Fig. 1From: Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinomaClinicopathological and genomic characteristics of the surgery cohort. A Illustration of clinicopathological and genomic characteristics of the surgery cohort. Tumor mutational burden is shown in the upper panel. Basic clinicopathological characteristics are illustrated in the middle panel. Mutations with high frequencies are depicted in the lower panel. B Enriched genes mutated in concordant dMMR/MSI-H samples (highlighted in pink) or pMMR/MSS samples (highlighted in blue). C TMB, CNV, and fusion in concordant dMMR/MSI-H samples, discordant samples, and concordant pMMR/MSS samples. D Heatmap of the number of mutations in pre-specified pathways in concordant samples. Abbreviations: dMMR, mismatch repair-deficient; EBV, Epstein-Barr virus; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; MLH1, MutL homolog 1; MMR, mismatch repair; MSH2, MutS Homolog 2; MSH6, MutS Homolog 6; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stability; N.A., not applicable; NGS, next-generation sequencing; PCR, polymerase chain reaction; PMS2, PMS1 Homolog 2; TMB, tumor mutational burden; CNV, copy number variationBack to article page